Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
MONROVIA, Calif.--(BUSINESS WIRE)--Jan 4, 2023--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.
A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website. A replay will be available for at least 30 days following the presentation.
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor’s XmAb ® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230104005829/en/
CONTACT: Charles Liles
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH PHARMACEUTICAL ONCOLOGY
SOURCE: Xencor, Inc.
Copyright Business Wire 2023.
PUB: 01/04/2023 04:01 PM/DISC: 01/04/2023 04:00 PM